Chemotherapy

Positive results from the RETAIN-2 trial demonstrate that a response-adapted bladder-preservation approach involving neoadjuvant chemoimmunotherapy can be considered in select patients

There are currently no approved maintenance therapies for metastatic and recurrent uterine/endometrial cancer

Adding atezolizumab immunotherapy to postsurgery chemotherapy doesn’t have the same benefits as the pre-surgery regimen

The treatment significantly increases the survival of people with malignant mesothelioma, according to results from Phase 3 trial

Venetoclax administered with bendamustine+rituximab as the first therapy for mantle cell lymphoma led to 85 percent complete response rate

The HER2CLIMB-02 trial reveals significant benefits, especially for breast cancer patients with brain metastases

Trials showed the effect of combination therapy on survival and quality of life in children with low- and high-grade gliomas

Prospective trials may help assess whether molecular subtype-directed approach can improve response to neoadjuvant therapy in MIBC patients

The novel therapeutic could provide a new option for patients with treatment-resistant KRAS gene mutation-positive colorectal cancer